Alemtuzumab

also known as Campath-1H · Campath · ALLO-647 · MabCampath · Alemtuzumab (Campath) · Campath-IH · alemtuzumab (Campath, Lemtrada) · Campath-1H (Alemtuzumab) · +2 more

Monoclonal antibody targets CD52

Developed for: leukemia · B-cell chronic lymphocytic leukemia · myelodysplastic syndrome · lymphoma · sickle cell disease · chronic lymphocytic leukemia/small lymphocytic lymphoma · peripheral T-cell lymphoma, not otherwise specified · plasma cell myeloma
+119 more
· relapsing-remitting multiple sclerosis · graft versus host disease · Hodgkins lymphoma · acute myeloid leukemia · immunodeficiency disease · myelodysplastic/myeloproliferative disease · non-Hodgkin lymphoma · acute lymphoblastic leukemia · chronic myeloid leukemia · disease related to hematopoietic stem cell transplant · multiple sclerosis · type 1 diabetes mellitus · adult T-cell leukemia/lymphoma · aplastic anemia · chronic granulomatous disease · plasma cell neoplasm · T-cell prolymphocytic leukemia · angioimmunoblastic T-cell lymphoma · beta thalassemia · hematopoietic and lymphoid cell neoplasm · juvenile myelomonocytic leukemia · myeloproliferative neoplasm · neuroblastoma · ovarian cancer · paroxysmal nocturnal hemoglobinuria · severe combined immunodeficiency · T-cell non-Hodgkin lymphoma · thalassemia · Waldenstrom macroglobulinemia · Wiskott-Aldrich syndrome · acute undifferentiated leukemia · adult acute lymphoblastic leukemia · anaplastic large cell lymphoma · bone marrow failure syndrome · Burkitt lymphoma · Chediak-Higashi syndrome · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · common variable immunodeficiency · Diamond-Blackfan anemia · disease related to solid organ transplantation · extranodal nasal NK/T cell lymphoma · Fanconi anemia · grade III lymphomatoid granulomatosis · hairy cell leukemia · hemophagocytic syndrome · hepatosplenic T-cell lymphoma · hyper-IgM syndrome · immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome · inborn errors of metabolism · Langerhans cell histiocytosis · large-cell immunoblastic lymphoma · liver disorder · lymphoblastic lymphoma · lymphoproliferative syndrome · MALT lymphoma · mantle cell lymphoma · mycosis fungoides and variants · myelofibrosis · nodal marginal zone B-cell lymphoma · severe congenital neutropenia · splenic marginal zone lymphoma · T-cell adult acute lymphocytic leukemia · T-cell large granular lymphocyte leukemia · transplant rejection · X-linked lymphoproliferative syndrome · acquired aplastic anemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute promyelocytic leukemia · acute transplant rejection · anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · autoimmune hemolytic anemia · autoimmune lymphoproliferative syndrome · autoimmune thrombocytopenic purpura · benign neoplasm · beta-thalassemia major · Bruton-type agammaglobulinemia · childhood myelodysplastic syndrome · chronic graft versus host disease · classic Hodgkin lymphoma · congenital amegakaryocytic thrombocytopenia · Crohn disease · DiGeorge syndrome · Epstein-Barr virus infection · fallopian tube cancer · granulomatosis with polyangiitis · hemolytic anemia · high grade B-cell lymphoma · histiocytosis · Hoyeraal-Hreidarsson syndrome · hyper-IgM syndrome type 1 · idiopathic aplastic anemia · immune dysregulation, autoimmunity, and autoinflammation · inclusion body myositis · inherited hemoglobinopathy · intraocular lymphoma · kidney cancer · leukocyte adhesion deficiency · mast cell leukemia · microscopic polyangiitis · mycosis fungoides · myeloproliferative neoplasm, unclassifiable · peritoneum cancer · polyneuropathy, inflammatory demyelinating, chronic · precursor lymphoblastic lymphoma/leukemia · premalignant hematological system disease · primary cutaneous B-cell lymphoma · primary cutaneous T-cell lymphoma · primary cutaneous T-cell non-Hodgkin lymphoma · renal cell carcinoma · Revesz syndrome · rheumatoid arthritis · Sezary syndrome · small intestine lymphoma · testicular lymphoma · vasculitis · end stage renal failure
Investigated by: National Cancer Institute (NCI) · Genzyme, a Sanofi Company · Bayer · M.D. Anderson Cancer Center · National Heart, Lung, and Blood Institute (NHLBI) · Baylor College of Medicine
+151 more
· Northwestern University · German CLL Study Group · The Methodist Hospital Research Institute · University of Wisconsin, Madison · Dana-Farber Cancer Institute · Masonic Cancer Center, University of Minnesota · Mayo Clinic · Center for Cell and Gene Therapy, Baylor College of Medicine · Fred Hutchinson Cancer Center · National Institute of Allergy and Infectious Diseases (NIAID) · Allogene Therapeutics · University of Chicago · Astellas Pharma Inc · Cancer Research UK · Case Comprehensive Cancer Center · Children's Hospital Medical Center, Cincinnati · Columbia University · Hospital Universitario Dr. Jose E. Gonzalez · Immune Tolerance Network (ITN) · Spanish Lymphoma Cooperative Group · University of Alberta · University of Miami · Alliance for Clinical Trials in Oncology · Assistance Publique - Hôpitaux de Paris · Beth Israel Deaconess Medical Center · CABYC · Children's Hospital of Philadelphia · City of Hope Medical Center · David Rizzieri, MD · Dr. Claudia Bösmüller · Eastern Cooperative Oncology Group · GlaxoSmithKline · Johns Hopkins University · Juvenile Diabetes Research Foundation · Karolinska University Hospital · Massachusetts General Hospital · National Comprehensive Cancer Network · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Nationwide Children's Hospital · Ohio State University Comprehensive Cancer Center · Study Group of Medical Tumour Therapy (AGMT) · University of Arizona · University of California, Los Angeles · University of California, San Francisco · University of Cologne · University of Göttingen · Washington University School of Medicine · Aarhus University Hospital · Alberta Children's Hospital · Alberta Innovates Health Solutions · Allan D Kirk, MD, PhD · American Society of Transplant Surgeons · Ann & Robert H Lurie Children's Hospital of Chicago · Arizona Oncology Associates · Astex Pharmaceuticals, Inc. · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Berlex Laboratories, Inc. · Blood and Marrow Transplant Clinical Trials Network · Boston Children's Hospital · Brigham and Women's Hospital · Bristol-Myers Squibb · Cambridge University Hospitals NHS Foundation Trust · Carelon Research · Central Texas Neurology Consultants · Cephalon · Charite University, Berlin, Germany · Children's Hospital Los Angeles · Children's Hospital at Montefiore · Children's Mercy Hospital Kansas City · Chronic Lymphocytic Leukemia Research Consortium · Clinical Trials in Organ Transplantation · Cooperative Clinical Trials in Pediatric Transplantation · Damiano Rondelli, MD · Deutsche Klinik fuer Diagnostik · all 157 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	LEMTRADA	—	2007-09-19 – 2018-11-28	fda.gov ↗
Approved	EU (EMA)	MabCampath	—	2001-07-06	europa.eu ↗
Approved	US (FDA)	LEMTRADA	—	2001-05-07	fda.gov ↗

Trials 213 · started per year

today

US approved 2001

EU approved 2001

20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT03910452	Oct 2019 → Jun 2034 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	No outcome recorded
Phase 0	NCT02653196	Sep 2015 → Aug 2017	neuroepithelial neoplasm	Montefiore Medical Center	Terminated	No outcome recorded
Phase 0	NCT00426517	Jan 2007 → Nov 2019	immunodeficiency disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 120 trials
Phase 1	NCT05384756	Jul 2022 → Dec 2026 expected	sickle cell disease	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT04696731	Feb 2021 → Jan 2030 expected	clear cell renal carcinoma	Allogene Therapeutics	Active not recruiting	No outcome recorded
Phase 1	NCT03989466	Jan 2020 → Sep 2024	T-cell prolymphocytic leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT03939026	May 2019 → Oct 2021	large B-cell lymphoma	Allogene Therapeutics	Completed	No outcome recorded
Phase 1	NCT03132584	Jul 2017 → Jan 2018	high grade B-cell lymphoma	Dana-Farber Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02689453	Jan 2017 → Jun 2021	T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT02583594	Dec 2015 → Mar 2016	multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT01624714	Sep 2012 → Apr 2017	multiple sclerosis	Samuel Forrester Hunter, MD, PhD	Unknown	No outcome recorded
Phase 1	NCT00923182	Feb 2010 → Aug 2011	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT00947388	Nov 2008 → Sep 2012	chronic lymphocytic leukemia/small lymphocytic lymphoma	Case Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00637390	Mar 2008 → Oct 2010	fallopian tube cancer, ovarian cancer, peritoneum cancer	University of Michigan Rogel Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00495755	Jul 2007 → Oct 2011	chronic graft versus host disease	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00562068	May 2007 → May 2009	lymphoma, small intestine cancer	Cancer Research UK	Unknown	No outcome recorded
Phase 1	NCT00458250	Sep 2006 → Feb 2008	acute lymphoblastic leukemia, acute myeloid leukemia	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 1	NCT00330252	May 2006 → Jan 2013	chronic lymphocytic leukemia/small lymphocytic lymphoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00214214	Oct 2005 → ?	type 1 diabetes mellitus	University of Wisconsin, Madison	Withdrawn	No outcome recorded
Phase 1	NCT00161590	Jul 2004 → ?	T-cell non-Hodgkin lymphoma	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1	NCT00323323	Mar 2004 → Aug 2012	non-Hodgkin lymphoma	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT00278512	Aug 2003 → Jun 2016	vasculitis	Northwestern University	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00282412	Sep 2002 → Jun 2016	rheumatoid arthritis	Northwestern University	Terminated	No outcome recorded Stop: Enrollment

Phase 1/233 trials · 1 met primary
Phase 1/2	NCT07599176	Jul 2026 → Jun 2032 expected	beta thalassemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 1/2	NCT05000450	Jun 2021 → Oct 2023	refractory plasma cell neoplasm	Allogene Therapeutics	Terminated	No outcome recorded
Phase 1/2	NCT03182426	Aug 2017 → Jul 2024	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT03077542	Apr 2017 → Jul 2023 overdue	sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT02472054	Jun 2015 → Sep 2019	hemophagocytic syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT02061800	Jun 2013 → Jul 2026 overdue	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +1	Diane George	Active not recruiting	No outcome recorded
Phase 1/2	NCT01269385	Jan 2011 → Jun 2014	B-cell chronic lymphocytic leukemia	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00983528	Sep 2009 → Sep 2011	acute lymphoblastic leukemia	University of California, San Diego	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00935792	Jul 2009 → Dec 2015	B-cell chronic lymphocytic leukemia	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00951457	Mar 2009 → Aug 2012	B-cell chronic lymphocytic leukemia	Study Group of Medical Tumour Therapy (AGMT)	Completed	No outcome recorded
Phase 1/2	NCT02435901	Dec 2008 → Mar 2019	beta-thalassemia major, sickle cell disease	Northwell Health	Completed	No outcome recorded
Phase 1/2	NCT00520130	Oct 2007 → Oct 2015	Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1	National Cancer Institute (NCI)	Completed	Met primary
Phase 1/2	NCT00579137	Oct 2007 → Oct 2009	Wiskott-Aldrich syndrome, severe combined immunodeficiency	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00555048	Sep 2007 → Oct 2010	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00773149	Oct 2006 → Jan 2011	acute lymphoblastic leukemia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT00453427	Sep 2006 → Jun 2013	peripheral T-cell lymphoma, not otherwise specified	Ontario Clinical Oncology Group (OCOG)	Completed	No outcome recorded
Phase 1/2	NCT00363090	Sep 2006 → Dec 2010	lymphoma	Toronto Sunnybrook Regional Cancer Centre	Unknown	No outcome recorded
Phase 1/2	NCT00085449	May 2006 → Jan 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Alliance for Clinical Trials in Oncology	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00943592	Mar 2006 → Apr 2011	leukemia, premalignant hematological system disease	University of Chicago	Completed	No outcome recorded
Phase 1/2	NCT00061568	Jul 2004 → Jan 2023 overdue	hemolytic anemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT00167661	Jun 2004 → Dec 2011	disease related to solid organ transplantation	University of Wisconsin, Madison	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00077961	Dec 2003 → Feb 2006	non-Hodgkin lymphoma	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 1/2	NCT00634881	Nov 2003 → Jan 2010	chronic lymphocytic leukemia/small lymphocytic lymphoma	German CLL Study Group	Completed	No outcome recorded
Phase 1/2	NCT00078559	Nov 2003 → Feb 2010	kidney disorder	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 1/2	NCT00061945	Jun 2003 → Dec 2007	B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00051701	Dec 2002 → Aug 2005	non-Hodgkin lymphoma	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 1/2	NCT00056966	Nov 2002 → May 2005	hematopoietic and lymphoid cell neoplasm	Baylor College of Medicine	Completed	No outcome recorded
Phase 1/2	NCT00056979	Jun 2002 → Jun 2003	inborn errors of metabolism	Baylor College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00590460	Jul 2001 → Sep 2009	Fanconi anemia	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00048399	Dec 2000 → Oct 2003	disease related to hematopoietic stem cell transplant	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00058825	Aug 2000 → Sep 2014	hematopoietic and lymphoid cell neoplasm	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00048412	Jun 2000 → Nov 2004	leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, plasma cell myeloma	Baylor College of Medicine	Completed	No outcome recorded

Phase 2113 trials · 4 met primary · 2 missed
Phase 2	NCT06872333	Nov 2024 → Jun 2030 expected	disease related to hematopoietic stem cell transplant, sickle cell disease	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05714345	Nov 2023 → Feb 2024	large B-cell lymphoma	Allogene Therapeutics	Terminated	No outcome recorded Stop: Business
Phase 2	NCT05501756	Jan 2023 → Aug 2028 expected	disease related to hematopoietic stem cell transplant	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT04154735	Nov 2019 → Mar 2023	Crohn disease	Northwestern University	Withdrawn	No outcome recorded
Phase 2	NCT04018937	Mar 2019 → Nov 2026 expected	sickle cell disease	Emory University	Active not recruiting	No outcome recorded
Phase 2	NCT03579875	Nov 2018 → Jan 2027 expected	Fanconi anemia, TCR-alpha-beta-positive T-cell deficiency, bone marrow failure syndrome, dyskeratosis congenita +2	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT03587272	Apr 2018 → Nov 2030 expected	sickle cell disease	Robert Nickel	Recruiting	No outcome recorded
Phase 2	NCT02385110	Sep 2015 → Jan 2023	leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT02171104	Jul 2014 → Jan 2026 overdue	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease, type C2 +15	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
Phase 2	NCT02105766	Apr 2014 → Dec 2023 overdue	graft versus host disease, sickle cell disease, thalassemia	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Show all 113 trials opens the full record — a long page
Phase 2/34 trials
Phase 2/3	NCT01120028	Sep 2010 → Feb 2014	—	University of Oxford	Completed	Mixed
Phase 2/3	NCT00749112	Aug 2008 → Aug 2010	autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura	Hospital Universitario Dr. Jose E. Gonzalez	Completed	No outcome recorded
Phase 2/3	NCT00454480	Aug 2006 → Aug 2012	leukemia, myelodysplastic syndrome	The University of New South Wales	Completed	No outcome recorded
Phase 2/3	NCT00354120	Mar 2005 → Aug 2011	acute myeloid leukemia, chronic myeloid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +2	Italian Group for Bone Marrow Transplantation	Completed	No outcome recorded
Phase 311 trials · 2 met primary
Phase 3	NCT01333358	May 2011 → Dec 2013	multiple sclerosis	Central Texas Neurology Consultants	Unknown	No outcome recorded
Phase 3	NCT00930553	Aug 2009 → Feb 2016	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00646854	Jun 2008 → Dec 2016	peripheral T-cell lymphoma, not otherwise specified	Aarhus University Hospital	Completed	No outcome recorded
Phase 3	NCT00725231	Feb 2008 → Mar 2014	angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified	University of Göttingen	Unknown	No outcome recorded
Phase 3	NCT00548405	Oct 2007 → Sep 2011	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	Met primary
Phase 3	NCT00530348	Aug 2007 → Apr 2011	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	Mixed
Phase 3	NCT00316810	Apr 2006 → Feb 2011	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00086580	Jul 2004 → Jun 2010	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	Met primary
Phase 3	NCT00226512	Jul 2004 → ?	acute myeloid leukemia, myelodysplastic syndrome	Hadassah Medical Organization	Withdrawn	No outcome recorded
Phase 3	NCT00147381	Jan 2004 → Aug 2008	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00046683	Jul 2001 → Jun 2006	B-cell chronic lymphocytic leukemia	Genzyme, a Sanofi Company	Completed	No outcome recorded

Phase 415 trials · 1 missed
Phase 4	NCT03535298	Jan 2019 → Jul 2027 expected	relapsing-remitting multiple sclerosis	The Cleveland Clinic	Active not recruiting	No outcome recorded
Phase 4	NCT03135249	May 2018 → Nov 2020	multiple sclerosis	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT02419378	Jun 2015 → Jul 2020	relapsing-remitting multiple sclerosis	University Hospital Muenster	Completed	No outcome recorded
Phase 4	NCT02255656	Jan 2015 → Jul 2020	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT02205489	Oct 2014 → Apr 2016	relapsing-remitting multiple sclerosis	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01757574	Nov 2012 → Aug 2016	polyneuropathy, inflammatory demyelinating, chronic	Johns Hopkins University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01729494	Sep 2012 → Dec 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT01395316	Jun 2011 → Oct 2015	multiple sclerosis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT01405807	Feb 2011 → Mar 2014	granulomatosis with polyangiitis, microscopic polyangiitis	Cambridge University Hospitals NHS Foundation Trust	Unknown	No outcome recorded
Phase 4	NCT01172418	Feb 2006 → May 2010	—	University of Miami	Completed	Missed primary
Phase 4	NCT01213329	Feb 2006 → Apr 2009	—	Northwestern University	Terminated	No outcome recorded
Phase 4	NCT00113269	May 2005 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00177138	Jul 2004 → Nov 2006	diabetes mellitus	University of Minnesota	Terminated	No outcome recorded
Phase 4	NCT00685061	Nov 2002 → Sep 2004	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00681343	Sep 2002 → Oct 2006	—	University of Miami	Completed	No outcome recorded

Phase not applicable14 trials
—	NCT03302754	Oct 2017 → Mar 2019	disease related to hematopoietic stem cell transplant	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
—	NCT02179359	Sep 2014 → Nov 2024	Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01652092	Sep 2012 → Dec 2025 overdue	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, Omenn syndrome +6	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
—	NCT01408342	Jul 2011 → Jan 2013	aplastic anemia	Hospital Universitario Dr. Jose E. Gonzalez	Withdrawn	No outcome recorded
—	NCT01042509	Oct 2009 → Oct 2011	graft versus host disease	Hospital Universitario Dr. Jose E. Gonzalez	Completed	No outcome recorded
—	NCT00619528	Jan 2008 → Jul 2022	immunodeficiency disease, transplant rejection	Northwestern University	Completed	No outcome recorded
—	NCT00336206	Jul 2006 → Oct 2009	B-cell chronic lymphocytic leukemia	Tawam Hospital	Unknown	No outcome recorded
—	NCT00579592	Apr 2006 → Mar 2007	acute transplant rejection	University of Wisconsin, Madison	Terminated	No outcome recorded
—	NCT00582894	Feb 2005 → Mar 2008	disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm	University of Oklahoma	Completed	No outcome recorded
—	NCT00525876	Jan 2005 → Sep 2010	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00073879	Apr 2003 → Apr 2004	kidney cancer	Baylor College of Medicine	Completed	No outcome recorded
—	NCT00038844	Jun 2001 → Dec 2007	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00038883	Apr 2001 → May 2006	T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
—	NCT00021151	Jan 2000 → Apr 2001	leukemia	Case Comprehensive Cancer Center	Completed	No outcome recorded

Comparator or background therapy86 trials
Phase 0	NCT03421756 Background	Mar → Sep 2018	sickle cell disease	Kathleen Dorritie	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT00881556 Background	Aug 2009 → Sep 2015	epidermolysis bullosa	Columbia University	Terminated	No outcome recorded
Phase 1	NCT04093596 Background	Sep 2019 → Jan 2025	refractory plasma cell neoplasm	Allogene Therapeutics	Completed	No outcome recorded
Phase 1	NCT03504241 Background	Jul 2018 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT02867800 Background	Jul 2016 → Dec 2021	graft versus host disease, sickle cell disease	Monica Bhatia	Completed	No outcome recorded
Phase 1	NCT02678143 Background	Apr 2016 → Apr 2020	sickle cell disease	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT02165007 Background	Jan 2015 → Jan 2024	sickle cell-beta-thalassemia disease syndrome, thalassemia	Catherine Bollard	Completed	No outcome recorded
Phase 1	NCT01625351 Background	Aug 2012 → Feb 2020	Ewing sarcoma, Wilms tumor, clear cell adenocarcinoma, germ cell tumor +7	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00744692 Background	Oct 2008 → Dec 2012	bone marrow failure syndrome, immunodeficiency disease, lysosomal storage disease, sickle cell disease +1	Duke University	Completed	No outcome recorded
Phase 1	NCT00104975 Background	Feb 2005 → May 2008	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm	Yale University	Completed	No outcome recorded
Phase 1	NCT00152100 Background	Feb 2004 → Aug 2007	severe combined immunodeficiency	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00057005 Background	Feb 2003 → Oct 2009	leukemia	Baylor College of Medicine	Completed	No outcome recorded
Phase 1	NCT00586274 Background	Mar 2002 → Jul 2009	Fanconi anemia	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT06959771 Background	Jul 2025 → Oct 2027 expected	hyper-IgM syndrome type 1	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT05463133 Background	Jul 2022 → Dec 2032 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT05357482 Background	May 2022 → Jan 2026 overdue	beta thalassemia, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT04416984 Background	May 2020 → Feb 2029 expected	B-cell non-Hodgkin lymphoma	Allogene Therapeutics	Active not recruiting	No outcome recorded
Phase 1/2	NCT03653338 Background	Aug 2018 → Aug 2026 overdue	Diamond-Blackfan anemia, beta-thalassemia major, sickle cell disease	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT03500731 Background	Apr 2018 → Dec 2027 expected	chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT03128996 Background	Mar 2017 → Apr 2028 expected	bone marrow failure syndrome, metabolic disease, sickle cell disease	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT02629120 Comparator	Dec 2015 → Dec 2027 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	No outcome recorded
Phase 1/2	NCT02059239 Background	Jun 2014 → Dec 2019	Hodgkins lymphoma, non-Hodgkin lymphoma	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1/2	NCT01875237 Background	Dec 2013 → Mar 2017	leukemia, myeloproliferative neoplasm, plasma cell myeloma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT00692939 Background	Jun 2012 → Dec 2026 expected	Crohn disease	Paul Szabolcs	Recruiting	No outcome recorded
Phase 1/2	NCT01712945 Background	Jun 2012 → Aug 2017	multiple sclerosis	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded
Phase 1/2	NCT01499888 Background	Nov 2011 → Sep 2028 expected	sickle cell disease	University of Illinois at Chicago	Active not recruiting	No outcome recorded
Phase 1/2	NCT01446484 Background	Oct 2011 → Nov 2014	end stage renal failure, kidney failure	Pirogov Russian National Research Medical University	Unknown	No outcome recorded
Phase 1/2	NCT00977691 Background	Dec 2009 → Aug 2018 overdue	sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT00626626 Background	May 2007 → Jan 2010	Hodgkins lymphoma, chronic myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Milton S. Hershey Medical Center	Terminated	No outcome recorded
Phase 1/2	NCT00183248 Background	Sep 2004 → Nov 2009	kidney failure	University of Miami	Completed	No outcome recorded
Phase 1/2	NCT00920972 Background	Dec 2001 → Dec 2026 expected	inherited hemoglobinopathy, metabolic disease	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT00281983 Background	Jun 2000 → Jul 2010	B-cell chronic lymphocytic leukemia	German CLL Study Group	Completed	No outcome recorded
Phase 2	NCT06084780 Background	Nov 2026 → Dec 2027 expected	pseudomyxoma peritonei, retroperitoneal cancer	Case Comprehensive Cancer Center	Not yet recruiting	No outcome recorded
Phase 2	NCT07616154 Background	Sep 2026 → Sep 2034 expected	sickle cell disease	St. Jude Children's Research Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07284641 Background	May 2026 → May 2030 expected	DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT06358638 Background	Apr 2024 → Sep 2044 expected	sickle cell disease	Children's National Research Institute	Recruiting	No outcome recorded
Phase 2	NCT04971005 Comparator	Aug 2021 → Feb 2022	relapsing-remitting multiple sclerosis	University Medical Center Hamburg-Eppendorf	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04339777 Comparator	Sep 2020 → Oct 2026 expected	T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT04362293 Background	Apr 2020 → Jun 2026 overdue	sickle cell disease	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT04232085 Background	Feb 2020 → Dec 2027 expected	Fanconi anemia, Hoyeraal-Hreidarsson syndrome, bone marrow failure syndrome, dyskeratosis congenita and related telomere biology disorder +2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting	No outcome recorded
Phase 2	NCT03821610 Background	Nov 2018 → Oct 2025 overdue	acute lymphoblastic leukemia	University of Birmingham	Active not recruiting	No outcome recorded
Phase 2	NCT03630211 Background	Jul 2018 → Aug 2026 overdue	diffuse scleroderma, interstitial lung disease, pulmonary hypertension	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT03214354 Background	Jul 2017 → Jul 2028 expected	disease related to hematopoietic stem cell transplant, pure red-cell aplasia, sickle cell disease	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT02766465 Background	Mar 2017 → May 2023	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02694770 Comparator	Jul 2016 → Sep 2017	acute graft versus host disease	AbGenomics B.V Taiwan Branch	Withdrawn	No outcome recorded
Phase 2	NCT02626715 Comparator	Sep 2015 → Apr 2023	acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome	Randy Windreich	Completed	No outcome recorded
Phase 2	NCT02497404 Background	Feb 2015 → Jun 2020	acute erythroid leukemia, myelodysplastic syndrome	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 2	NCT01962415 Background	Feb 2014 → Nov 2026 expected	bone marrow failure syndrome, hereditary anemia, immunodeficiency disease, inborn errors of metabolism +1	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT01679041 Background	Nov 2012 → Nov 2013	multiple sclerosis	Seah Lim M.D.	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01889381 Background	Aug 2012 → Aug 2026 overdue	craniofacial and skeletal defects	Johns Hopkins University	Recruiting	No outcome recorded
Phase 2	NCT01596699 Background	May 2012 → Jun 2019	anemia, bone marrow failure syndrome, immune dysregulation, autoimmunity, and autoinflammation, immunodeficiency disease +2	University of California, San Francisco	Terminated	No outcome recorded
Phase 2	NCT01518153 Background	Feb 2012 → Aug 2014	leukemia, myeloproliferative neoplasm, plasma cell myeloma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT01256398 Background	Dec 2010 → Nov 2017	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01043640 Background	Dec 2009 → Jun 2015	Hurler syndrome, Krabbe disease, adrenoleukodystrophy, alpha-mannosidosis +4	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00986557 Background	Sep 2009 → Aug 2013	graft versus host disease	University Hospital Birmingham	Unknown	No outcome recorded
Phase 2	NCT00871546 Comparator	Mar 2009 → Dec 2010	B-cell chronic lymphocytic leukemia, mantle cell lymphoma	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00720447 Background	Nov 2008 → Nov 2010	lymphoma	Cancer Research UK	Unknown	No outcome recorded
Phase 2	NCT00745420 Background	Aug 2008 → Jul 2015	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT00668564 Background	Mar 2008 → Feb 2010	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease type C +5	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00638820 Background	Sep 2007 → May 2008	osteopetrosis	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00536978 Background	Sep 2007 → Nov 2010	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00441025 Comparator	Sep 2006 → Aug 2009	peripheral T-cell lymphoma, not otherwise specified	Mahidol University	Terminated	No outcome recorded
Phase 2	NCT00383448 Background	Sep 2006 → Sep 2014	GM1 gangliosidosis, Krabbe disease, Sandhoff disease, Tay-Sachs disease +5	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00818961 Background	May 2005 → Mar 2011	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Northside Hospital, Inc.	Terminated	No outcome recorded
Phase 2	NCT00578942 Background	May 2005 → Apr 2013	leukemia, myelodysplastic syndrome, plasma cell myeloma	David Rizzieri, MD	Completed	No outcome recorded
Phase 2	NCT00153985 Background	Mar 2004 → Mar 2008	sickle cell disease, thalassemia	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00578643 Background	Mar 2004 → Jul 2017	chronic granulomatous disease	Baylor College of Medicine	Completed	No outcome recorded
Phase 2	NCT00309270 Background	Feb 2003 → Apr 2010	—	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 2	NCT00176865 Comparator	Aug 2002 → Aug 2012	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00040469 Background	Aug 2000 → Nov 2003	sickle cell disease, thalassemia	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00368355 Background	Apr 2000 → Nov 2015	X-linked lymphoproliferative syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2	Baylor College of Medicine	Completed	No outcome recorded
Phase 2/3	NCT00775931 Comparator	Aug 2008 → Jun 2013	osteopetrosis	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00455312 Background	Aug 2007 → Mar 2015	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT01019876 Comparator	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 3	NCT04047628 Background	Aug 2020 → Oct 2026 expected	relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 3	NCT03477500 Comparator	Mar 2018 → Nov 2026 expected	multiple sclerosis	Haukeland University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT01877837 Background	Jun 2011 → Sep 2021	sickle cell disease	Hackensack Meridian Health	Completed	No outcome recorded
Phase 4	NCT01046955 Comparator	Nov 2005 → Apr 2007	end stage renal failure	University of Miami	Completed	No outcome recorded
Phase 4	NCT00166712 Comparator	Apr 2005 → Apr 2010	chronic transplant rejection	Northwestern University	Terminated	No outcome recorded Stop: Business
Phase 4	NCT00331162 Comparator	Feb 2005 → Nov 2011	transplant rejection	Wake Forest University Health Sciences	Completed	No outcome recorded
—	NCT02529839 Background	Oct 2015 → Oct 2017	multiple sclerosis	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT02162420 Background	Jan 2015 → Aug 2024	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT01626092 Background	Jul 2012 → Nov 2013	lysosomal storage disease, peroxisomal disease	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00578539 Background	Oct 2007 → May 2013	Hodgkins lymphoma, leukemia, myeloproliferative neoplasm, non-Hodgkin lymphoma	Baylor College of Medicine	Terminated	No outcome recorded
—	NCT00578344 Background	Jul 2005 → Jul 2012	sickle cell-hemoglobin c disease syndrome	Tami D. John	Terminated	No outcome recorded Stop: Enrollment
—	NCT00578292 Background	Feb 2004 → May 2016	thalassemia	Baylor College of Medicine	Terminated	No outcome recorded

News releases announcing trial results or a regulatory action · 20

Date	Issuer	Release
2026-06-11	Cellectis S.A.	Results Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress cellectis.com ↗ These encouraging data demonstrate that not only can eti-cel drive responses in a very difficult-to-treat population, but that by optimizing exposure to alemtuzumab we may be able to create a favorable environment for CAR-T expansion and persistence.
2025-11-03	Cellectis S.A.	Results Cellectis to Present a Development Update for eti-cel at ASH 2025 cellectis.com ↗ Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization of efficacy without an increase in toxicities
2025-08-01	Allogene Therapeutics	Results Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma allogene.com ↗ This decision, made ahead of the scheduled futility analysis, was prompted by a Grade 5 adverse event in the FC plus ALLO-647 arm that has been attributed to the use of ALLO-647.
2024-08-01	Cellectis S.A.	Regulatory FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment cellectis.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis’ CLLS52 (alemtuzumab)
2023-12-09	Allogene Therapeutics	Results Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology allogene.com ↗ The addition of ALLO-647 to standard lymphodepletion did not result in adverse events beyond those commonly observed with autologous CAR T cell therapy.
2023-11-02	Allogene Therapeutics	Results Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology allogene.com ↗ These results reinforce our belief that Allogene’s strategy of adding ALLO-647, an anti-CD52 monoclonal antibody candidate, to the standard fludarabine/cyclophosphamide (flu/cy) lymphodepletion regimen in our ALPHA/ALPHA2 studies can safely achieve this,
2023-05-02	Cellectis S.A.	Results Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting cellectis.com ↗ The data show that adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123 cell expansion, which correlated with improved activity.
2022-11-29	Allogene Therapeutics	Results Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform allogene.com ↗ A single infusion of CAR+ cells with FCA90 lymphodepletion regimen consisting of fludarabine (30 mg/m2/day x 3 days) and cyclophosphamide (300 mg/m2/day x 3 days) (standard flu/cy) plus 90 mg of ALLO-647 (Single Dose FCA90) was deemed preferrable to two infusions of CAR+ cells (Consolidation Regimen).
2022-11-03	Cellectis S.A.	Results Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 cellectis.com ↗ AMELI-01 (evaluating UCART123) abstract, selected for oral presentation, highlights that adding alemtuzumab was associated with improved activity
2021-12-11	Cellectis S.A.	Results Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting cellectis.com ↗
2021-11-04	Cellectis S.A.	Results Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 cellectis.com ↗ The data show that the addition of alemtuzumab to fludarabine and cyclophosphamide was well tolerated, deepened host T-cell depletion and promoted CAR-T cell expansion.
2021-11-03	Cellectis S.A.	Results Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01 cellectis.com ↗ The data show that the addition of alemtuzumab to fludarabine and cyclophosphamide was well tolerated, deepened host T-cell depletion and promoted CAR-T cell expansion.
2021-06-04	Allogene Therapeutics	Results Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology allogene.com ↗ No dose limiting toxicities or graft-vs-host disease (GvHD) were observed and one (2%) case of Grade 3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was reported.
2021-05-19	Allogene Therapeutics	Results Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021 allogene.com ↗ Safety and PK/PD Data of ALLO-647 with Flu/Cy Across ALPHA, ALPHA2 and UNIVERSAL (ALLO-715 in Multiple Myeloma) Trials Demonstrated Manageable Safety Profile; Exposure-Dependent Deep Lymphodepletion Correlated with AlloCAR T Cell Expansion and Clinical Responses
2020-12-05	Allogene Therapeutics	Results Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting allogene.com ↗ ALLO-715 with ALLO-647 Lymphodepletion Were Well Tolerated with No Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
2020-11-04	Allogene Therapeutics	Results Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology allogene.com ↗ Lower Dose (39mg) ALLO-647 Dose Dependent Activity Was Observed with 320M Cell Dose of ALLO-715 (DL3) Associated with a 60% Overall Response Rate (ORR)
2020-05-29	Allogene Therapeutics	Results Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting allogene.com ↗ ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
2020-05-13	Allogene Therapeutics	Results American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma allogene.com ↗ Three Patients Achieved a Complete Response (CR)
2018-12-03	Allogene Therapeutics	Results Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia allogene.com ↗ The analysis showed that 82 percent (14/17) of patients who received a lymphodepletion regimen consisting of fludarabine, cyclophosphamide and an anti-CD52 mAb (FCA) achieved a complete remission (CR) or complete remission with incomplete blood recovery (CRi).
2005-12-09	Astex Pharmaceuticals, Inc.	Results Studies of Nipent® in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting astx.com ↗ Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders

All press releases naming this drug 21 releases

Date	Issuer	Release
2026-06-11	Cellectis S.A.	Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress cellectis.com ↗
2025-11-03	Cellectis S.A.	Cellectis to Present a Development Update for eti-cel at ASH 2025 cellectis.com ↗
2025-08-01	Allogene Therapeutics	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma allogene.com ↗
2024-08-01	Cellectis S.A.	FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment cellectis.com ↗
2023-12-09	Allogene Therapeutics	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology allogene.com ↗
2023-11-02	Allogene Therapeutics	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology allogene.com ↗
2023-05-02	Cellectis S.A.	Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting cellectis.com ↗
2022-11-29	Allogene Therapeutics	Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform allogene.com ↗
2022-11-03	Cellectis S.A.	Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 cellectis.com ↗
2021-12-11	Cellectis S.A.	Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting cellectis.com ↗
2021-11-04	Cellectis S.A.	Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 cellectis.com ↗
2021-11-03	Cellectis S.A.	Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01 cellectis.com ↗
2021-06-04	Allogene Therapeutics	Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology allogene.com ↗
2021-05-19	Allogene Therapeutics	Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021 allogene.com ↗
2020-12-05	Allogene Therapeutics	Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting allogene.com ↗
2020-11-04	Allogene Therapeutics	Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology allogene.com ↗
2020-05-29	Allogene Therapeutics	Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting allogene.com ↗
2020-05-13	Allogene Therapeutics	American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma allogene.com ↗
2018-12-03	Allogene Therapeutics	Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia allogene.com ↗
2010-08-08	GlaxoSmithKline	GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia gsk.com ↗
2005-12-09	Astex Pharmaceuticals, Inc.	Studies of Nipent® in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting astx.com ↗

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 305 sources stand behind the page.

Field	Value	Cited text
Known as	Alemtuzumab	“This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine...” NCT00943592 ↗ 244 “Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea,...” PMID 24296492 ↗ Dec 2013 “After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were...” NCT00147901 ↗ “The study examines different conditioning approaches that vary in the timing and dosing of alemtuzumab (Campath), as well as disease-specific modifications for beta thalassemia...” NCT01050855 ↗ “Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1.” NCT01049854 ↗ “Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 that is FDA approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)” NCT00331162 ↗ “Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively” NCT00745420 ↗ “CAMPATH-1H (Alemtuzumab) is a recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52;” NCT00533923 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy.” NCT01459107 ↗ Show 234 more sources
Known as	Alemtuzumab (Campath)	“Alemtuzumab (Campath®)” NCT00997386 ↗ 1 “Alemtuzumab (Campath)” NCT01877837 ↗
Known as	alemtuzumab (Campath, Lemtrada)	“alemtuzumab (Campath®, Lemtrada®)” NCT04047628 ↗
Known as	ALLO-647	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05000450 ↗ 5 NCT04416984 ↗ NCT04696731 ↗ NCT05714345 ↗ NCT04093596 ↗ NCT03939026 ↗
Known as	Campath	“Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark])...” PMID 20659956 ↗ Jul 2010 21 “To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone...” NCT00161590 ↗ “The study examines different conditioning approaches that vary in the timing and dosing of alemtuzumab (Campath), as well as disease-specific modifications for beta thalassemia...” NCT01050855 ↗ “This study will examine the safety and effectiveness of alemtuzumab (Campath® (Registered Trademark)) for improving muscle strength in patients with sporadic inclusion body...” NCT00079768 ↗ “CAMPATH (alemtuzumab, MABCAMPATH, CAMPATH) administered intravenously (IV) once a week as treatment for relapsing or refractory non-Hodgkin's lymphoma (NHL).” NCT00051701 ↗ “Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 that is FDA approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)” NCT00331162 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days” NCT00206726 ↗ “Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia.” NCT01333358 ↗ “An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the CD52 protein” NCT00637390 ↗ Show 11 more sources
Known as	Campath-1H	“This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability to induce a state of permanent allograft acceptance, or tolerance, when administered...” NCT00001984 ↗ 69 “To translate IL-15-mediated increases in NK cells, we investigated combination therapy of IL-15 with anticancer monoclonal antibodies including rituximab in mouse models of...” PMID 32508818 ↗ May 2020 “This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia...” PMID 11986207 ↗ May 2002 “The purpose of this study is to evaluate the use of alemtuzumab (Campath-1H) for induction therapy in kidney and pancreas transplantation compared to our standard of care,...” NCT00331162 ↗ “Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell surface protein present at high density on most normal and malignant B and T lymphocytes.” NCT00930605 ↗ “Campath-1H (alemtuzumab) given subcutaneously during post-remission intensification treatment of adults with acute lymphoblastic leukemia (ALL).” NCT00061945 ↗ “CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body.” NCT00040469 ↗ “A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL” NCT00858117 ↗ “Our group has combined the above combination of fludarabine and cyclophosphamide with the antibody CAMPATH 1H.” NCT00578942 ↗ “Our group has combined the above combination of fludarabine and cyclophosphamide with the antibody CAMPATH 1H.” NCT00580034 ↗ “Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma” NCT00193466 ↗ Show 59 more sources
Known as	Campath-1H (Alemtuzumab)	“Campath-1H (Alemtuzumab)” NCT01172418 ↗
Known as	Campath-IH	“Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.” NCT00142181 ↗ 1 “Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17” NCT02435901 ↗
Known as	Lemtrada (alemtuzumab)	“Lemtrada (alemtuzumab)” NCT03535298 ↗
Known as	Mab- Campath (Alemtuzumab)	“Mab- Campath (Alemtuzumab)” NCT01679860 ↗
Known as	MabCampath	“CAMPATH (alemtuzumab, MABCAMPATH, CAMPATH) administered intravenously (IV) once a week as treatment for relapsing or refractory non-Hodgkin's lymphoma (NHL).” NCT00051701 ↗ 5 “Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia.” NCT01333358 ↗ “Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia” NCT00634881 ↗ “Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil” NCT00046683 ↗ “the monoclonal antibody MabCampath® (alemtuzumab)” NCT00646854 ↗ “Alemtuzumab (MabCampath)” NCT00199030 ↗
Action	Deplete	“Its administration temporarily depletes mature lymphocytes and some monocytes” NCT00001984 ↗
Modality	Monoclonal antibody	“This protocol will test a humanized monoclonal antibody known as Campath-1H” NCT00001984 ↗
Route	Intravenous	“Alemtuzumab was administered intravenously” NCT00001984 ↗
Target	CD52	“The humanized anti-CD52 monoclonal antibody alemtuzumab” PMID 19863336 ↗ Oct 2009